Dynavax Technologies (DVAX) | Financial Analysis & Statements
Dynavax Technologies Corporation Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Sep 2025Income Metrics
Revenue
94.9M
Gross Profit
80.5M
84.82%
Operating Income
21.3M
22.42%
Net Income
26.9M
28.38%
EPS (Diluted)
$0.21
Balance Sheet Metrics
Total Assets
945.9M
Total Liabilities
415.0M
Shareholders Equity
530.9M
Debt to Equity
0.78
Cash Flow Metrics
Operating Cash Flow
-101.7M
Free Cash Flow
-23.6M
Revenue & Profitability Trend
Quarter Income Flow
Sep 30, 2025
Annual Income Flow
2024
Dynavax Technologies Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 277.2M | 232.3M | 722.7M | 439.4M | 46.6M |
| Cost of Goods Sold | 49.4M | 50.2M | 262.2M | 173.6M | 13.9M |
| Gross Profit | 227.8M | 182.1M | 460.5M | 265.9M | 32.6M |
| Gross Margin % | 82.2% | 78.4% | 63.7% | 60.5% | 70.1% |
| Operating Expenses | |||||
| Research & Development | 61.6M | 54.9M | 46.6M | 32.2M | 28.6M |
| Selling, General & Administrative | 170.4M | 152.9M | 131.4M | 100.2M | 79.3M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 231.9M | 207.8M | 178.0M | 132.4M | 107.9M |
| Operating Income | -4.1M | -25.7M | 282.5M | 133.5M | -75.2M |
| Operating Margin % | -1.5% | -11.1% | 39.1% | 30.4% | -161.6% |
| Non-Operating Items | |||||
| Interest Income | 36.5M | 32.0M | 7.9M | 140.0K | 1.3M |
| Interest Expense | 6.8M | 6.8M | 6.7M | 11.2M | 19.1M |
| Other Non-Operating Income | 5.3M | -3.9M | 10.6M | -44.9M | 17.8M |
| Pre-tax Income | 30.9M | -4.4M | 294.3M | 77.5M | -75.2M |
| Income Tax | 3.5M | 2.0M | 1.1M | 808.0K | 0 |
| Effective Tax Rate % | 11.5% | 0.0% | 0.4% | 1.0% | 0.0% |
| Net Income | 27.3M | -6.4M | 293.2M | 76.7M | -75.2M |
| Net Margin % | 9.9% | -2.8% | 40.6% | 17.5% | -161.6% |
| Key Metrics | |||||
| EBITDA | 45.7M | 21.0M | 304.9M | 149.3M | -57.8M |
| EPS (Basic) | $0.21 | $-0.05 | $2.32 | $0.62 | $-0.75 |
| EPS (Diluted) | $0.20 | $-0.05 | $1.97 | $0.57 | $-0.78 |
| Basic Shares Outstanding | 130047000 | 128733000 | 126398000 | 116264000 | 100753000 |
| Diluted Shares Outstanding | 130047000 | 128733000 | 126398000 | 116264000 | 100753000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Dynavax Technologies Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 95.9M | 150.3M | 202.0M | 436.2M | 32.1M |
| Short-term Investments | 618.0M | 592.0M | 422.4M | 109.8M | 133.0M |
| Accounts Receivable | 45.3M | 40.6M | 145.1M | 116.2M | 22.3M |
| Inventory | 70.1M | 53.3M | 59.4M | 61.3M | 63.7M |
| Other Current Assets | 18.1M | 19.0M | 85.6M | 73.8M | - |
| Total Current Assets | 848.9M | 859.1M | 917.0M | 972.5M | 290.0M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 39.8M | 42.9M | 43.2M | 41.0M | 43.4M |
| Goodwill | 3.9M | 4.1M | 4.0M | 4.2M | 4.6M |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 74.8M | 74.3M | 3.5M | 3.6M | 3.8M |
| Total Non-Current Assets | 137.3M | 138.0M | 68.9M | 66.7M | 63.3M |
| Total Assets | 986.3M | 997.1M | 985.8M | 1.0B | 353.3M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 9.1M | 5.2M | 3.2M | 2.6M | 3.3M |
| Short-term Debt | 4.2M | 4.5M | 3.6M | 2.6M | 3.2M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 22.0K | 24.0K | - | 18.0M | 10.7M |
| Total Current Liabilities | 78.6M | 62.2M | 150.1M | 556.4M | 77.4M |
| Non-Current Liabilities | |||||
| Long-term Debt | 250.2M | 252.4M | 254.4M | 254.8M | 214.6M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 244.0K | 74.0K | 384.0K | 5.7M | 2.6M |
| Total Non-Current Liabilities | 310.8M | 312.8M | 254.8M | 260.5M | 217.2M |
| Total Liabilities | 389.5M | 375.0M | 404.8M | 816.9M | 294.6M |
| Equity | |||||
| Common Stock | 125.0K | 130.0K | 128.0K | 123.0K | 110.0K |
| Retained Earnings | -903.3M | -930.6M | -924.2M | -1.2B | -1.3B |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 596.8M | 622.1M | 581.0M | 222.4M | 58.7M |
| Key Metrics | |||||
| Total Debt | 254.4M | 256.9M | 258.0M | 257.4M | 217.8M |
| Working Capital | 770.3M | 796.9M | 766.9M | 416.1M | 212.6M |
Balance Sheet Composition
Dynavax Technologies Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 27.3M | -6.4M | 293.2M | 76.7M | -75.2M |
| Depreciation & Amortization | 8.1M | 7.3M | 6.7M | 7.1M | 9.3M |
| Stock-Based Compensation | 52.6M | 42.6M | 32.9M | 21.3M | 13.5M |
| Working Capital Changes | -24.0M | 46.1M | -400.3M | 198.4M | -4.5M |
| Operating Cash Flow | 70.0M | 90.7M | -66.5M | 305.1M | -53.2M |
| Investing Activities | |||||
| Capital Expenditures | -6.4M | -4.1M | -7.1M | -9.5M | -4.1M |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | -524.1M | -636.9M | -632.3M | -164.9M | -201.8M |
| Investment Sales | 512.4M | 486.1M | 322.4M | 187.6M | 179.5M |
| Investing Cash Flow | -18.0M | -154.9M | -317.0M | 13.2M | -26.4M |
| Financing Activities | |||||
| Share Repurchases | -100.0M | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | 0 | 0 | 219.8M | 0 |
| Debt Repayment | - | 0 | 0 | -190.2M | 0 |
| Financing Cash Flow | -109.3M | -6.5M | 0 | 30.5M | 108.5M |
| Free Cash Flow | 60.2M | 96.5M | 55.6M | 326.1M | -103.3M |
| Net Change in Cash | -57.4M | -70.8M | -383.5M | 348.9M | 28.9M |
Cash Flow Trend
Dynavax Technologies Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
54.60
Forward P/E
46.97
Price to Book
3.41
Price to Sales
5.51
PEG Ratio
0.71
Profitability Ratios
Profit Margin
-13.13%
Operating Margin
24.77%
Return on Equity
-7.14%
Return on Assets
1.20%
Financial Health
Current Ratio
7.62
Debt to Equity
54.15
Beta
0.92
Per Share Data
EPS (TTM)
$-0.37
Book Value per Share
$4.55
Revenue per Share
$2.70
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| DVAX | 1.8B | 54.60 | 3.41 | -7.14% | -13.13% | 54.15 |
| Zoetis | 49.8B | 19.58 | 15.04 | 65.99% | 28.24% | 279.59 |
| Haleon Plc - ADR | 42.4B | 18.72 | 1.88 | 10.27% | 15.11% | 52.37 |
| BioCryst | 2.2B | 7.09 | -15.53 | -221.45% | 30.16% | -4.01 |
| Perrigo Company plc | 1.6B | 2,818.00 | 0.55 | -38.66% | -33.51% | 131.16 |
| Ani Pharmaceuticals | 1.8B | 24.08 | 3.10 | 16.16% | 8.87% | 116.19 |
Financial data is updated regularly. All figures are in the company's reporting currency.




